Private cancer therapy 'crowdfunding rise'

More people are raising money online to pay for cancer therapies not available on the NHS.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news

Related Links:

We present the first documented case of pembrolizumab-induced grade IV neutropenia. A 73-year-old women known for myositis, Crohn’s disease, and hypothyroidism and diagnosed with PD-L1 positive stage IV pulmonary adenocarcinoma is treated with Pembrolizumab. She develops grade IV neutropenia 2 weeks after her second infusion. She is therefore hospitalized and treated initially with corticosteroids, granulocyte colony-stimulating factor, and intravenous immunoglobulins. Given the persistent neutropenia, cyclosporine was added, but quickly stopped owing to fever. The patient recovered her neutrophils 6.5 weeks after he...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
Contributors : Matthias Dobbelstein ; Anusha SriramanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCDK4 inhibitors have reached clinical approval for cancer therapy. In parallel, the p53 antagonist Mdm2 remains an attractive target for anti-cancer therapy, including numerous clinical studies. The genes encoding Mdm2 and CDK4 are frequently co-amplified in human malignancies, most notably in liposarcomas, suggesting their combined targeting for therapy. Here we show, however, that small compounds that inhibit Mdm2 and CDK4 antagonize each other rather than synergize in their cytotoxi...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Publication date: Available online 16 August 2018Source: Pharmacology &TherapeuticsAuthor(s): Vassilios Myrianthopoulos, Konstantinos Evangelou, Panagiotis V.S. Vasileiou, Tomer Cooks, Theodoros P. Vassilakopoulos, Gerassimos A. Pangalis, Myrsini Kouloukoussa, Christos Kittas, Alexandros G. Georgakilas, Vassilis G. GorgoulisAbstractCellular senescence is a stress response mechanism ensuring homeostasis. Its temporal activation during embryonic development or normal adult life is linked with beneficial properties. In contrast, persistent (chronic) senescence seems to exert detrimental effects fostering aging and age-rel...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
In this study, we found that CD169+ macrophages depletion inhibited the growth of established Lewis lung carcinoma tumors in mice. Benefits must be weighed against potential adverse effects in cancer therapy. Here, we investigated the adverse effects of CD169+ macrophages depletion on bone and bone marrow in mice bearing Lewis lung carcinoma tumors. Our studies showed that depletion of CD169+ macrophages in LLC tumor-bearing mice disrupted bone homeostasis, including bone weight loss and bone mineral density decrease. Further studies revealed that bone marrow erythropoiesis was severely impaired after depletion of CD169+ m...
Source: Cellular Immunology - Category: Allergy & Immunology Authors: Tags: Cell Immunol Source Type: research
Calpain 2 knockdown promotes cell apoptosis and restores gefitinib sensitivity through epidermal growth factor receptor/protein kinase B/survivin signaling. Oncol Rep. 2018 Aug 02;: Authors: Zhang G, Fang T, Chang M, Li J, Hong Q, Bai C, Zhou J Abstract Gefitinib, an epidermal growth factor receptor (EGFR)‑specific drug, is effective for ~1 year, after which resistance is inevitable. Calpain 2 (CAPN2) is known to serve a role in the drug response and resistance in certain cancer therapies. However, the full function of CAPN2, particularly in non‑small cell lung cancer, has not yet be...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
AbstractLiposomal therapies opened the chapter of nanomedicine, in 1995, with the approval of liposomal doxorubicin (Doxil®) for the treatment of numerous types of cancer. For the first time, liposomes permitted the employment of potent chemotherapeutic agents with improved pharmacokinetic and pharmacodynamic profiles, with less undesired side effects. Liposomal therapies allow the drug encapsulation and more selective delivery in the tumor bed, particularly due to the enhanced permeation and retention effect. These unique characteristics explain why liposomal therapies are being increasingly considered as alternatives...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ONCOLOGY recently interviewed Dr. Eileen Parkes, whose laboratory studies the STING pathway, to find out why researchers are excited about targeting this pathway as a potential cancer therapy.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
We describe the development of supercharged fluorescent protein modified water-soluble poly (N-phenylglycine) nanoparticles (SPNPG/ScGFP) as a novel nanotheranostic agent with highly effective cell penetration for image-guided photothermal cancer therapy. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
This article provides an overview of AZD1775, based on English peer-reviewed articles on MEDLINE. The authors highlight the data from the published preclinical and clinical studies. Expert opinion: A majority of the current clinical trials focus on AZD1775 combined with chemotherapy or radiation. Treatment with AZD1775 was tolerated and antitumor activity has been observed, especially in patients with advanced malignancies harboring G1 checkpoint aberrations and/or DNA damage repair defects. Thus, identification of the molecular subtypes that benefit most from the treatment with AZD1775 alone or in combination may provide ...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
Abstract Aneuploidy is a hallmark of cancer. Defects in chromosome segregation result in aneuploidy. Multiple pathways are engaged in this process, including errors in kinetochore-microtubule attachments, supernumerary centrosomes, spindle assembly checkpoint (SAC) defects, and chromosome cohesion defects. Although aneuploidy provides an adaptation and proliferative advantage in affected cells, excessive aneuploidy beyond a critical level can be lethal to cancer cells. Given this, enhanced chromosome missegregation is hypothesized to limit survival of aneuploid cancer cells, especially when compared to diploid cel...
Source: Annual Review of Pharmacology and Toxicology - Category: Drugs & Pharmacology Authors: Tags: Annu Rev Pharmacol Toxicol Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health